Skip to main content
Premium Trial:

Request an Annual Quote

Myriad s Q2 Revenues Jump as Losses Narrow

NEW YORK, Feb 6 – Myriad Genetics said Tuesday its fiscal second-quarter revenues jumped 44 percent to $12.0 million, compared with $8.3 million a year ago, as net losses narrowed significantly.  

Myriad of Salt Lake City attributed the increase in revenues to growth in predictive medicine revenue and new research collaborations launched over the past year. Revenue from predictive medicine increased by 96 percent for the quarter to $4.0 million, while research revenue jumped 28 percent to $8.0 million.

The company’s operating loss widened to $3.2 million, compared with $2.3 million a year ago, as expenses rose across the board. In the second quarter, the cost of predictive medicine revenue rose to $1.7 million, compared with $989,156 in the year ago period; R&D expenses jumped to $9.4 million, compared with $6.2 million; and selling, general, and administrative expenses increased to $4.1 million, compared with $3.4 million.

Net losses for the quarter totaled $1.2 million, or five cents a share, down 44 percent from $1.9 million, or nine cents a share, in the year ago period.

During the second quarter, Myriad announced that together with Syngenta it completed the sequence of the rice genome and added patents on a number of inventions. The company also extended a research collaboration with Bayer for the use of its ProNet proteomics technology.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.